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Lymphoreticular malignancies, collectively called 
posttransplant lymphoproliferative disorders (PTLD), 
eventually develop in 2-5% of organ transplant recip-
ients. They frequently undergo regression when im-
munosuppression is reduced or stopped. This feature 
has been associated with a previous or de novo Ep· 
stein·Barr virus (EBV) infection. We herein describe 
immunotherapy with autologous lymphokine·acti. 
vated killer (LAK) cells in seven patients with PTLD 
(four EBV.positive patients and three EBY.negative 
patients). Autologous peripheral blood mononuclear 
cells were obtained by leukapheresis, depleted of 
monocytes, and cultured in the presence of interleu· 
kin 2 for 10 to 11 days. A single dose of 5.2xl09 to 
5.6x 1010 LAK cells was given intravenously. Systemic 
interleukin 2 was not administered. 
The four patients with EBY+ PTLD had complete 
tumor regression; two of them developed controllable 
rejection. Three patients are well 13-16 months after 
treatment; the fourth patient died of pneumonia 41 
days after infusion. Three patients with EBY- lympho· 
mas had no response despite prior evidence that their 
tumors also were subject to immune surveillance. Two 
of these three patients died after being given other 
treatment, and the third patient has persistent tumor. 
In conclusion, autologous LAK cell infusion was ef· 
fective for treatment of four EBY+ organ transplant 
recipients. LAK cell efficacy for three patients with 
EBY- PTLD was not evaluable under the management 
circumstances in which this treatment was utilized. 
B cell lymphomas make up most of the hematolymphopoi-
etic tumors that collectively have been termed posttrans-
I This work was supported in part by NIH grant DK29961 and by 
funds from the Pathology Education and Research Foundation. Pitts· 
burgh. PA. 
2 Department of Pathology. University of Pittsburgh Medical Cen-
ter. 
3 Thomas E. StaTZI Transplantation Institute. 
• University of Pittsburgh Cancer Institute. 
, Department of Surgery. University of Pittsburgh Medical Cen· 
ter. 
e Laboratory of Tumor Biology. Karolinska Institute. 
7 Address correspondence to: Thomas E. Starzl. MD. PhD. Univer-
sity of Pittsburgh, 3601 Fifth Avenue. 4th Floor Falk Clinic, Pitts· 
burgh. PA 15213. 
Karolinska Institute. Stockholm. Sweden 
plant lymphoproliferative disorders (PTLDs*). These usually 
are of host origin following organ transplantation (1), includ· 
ing transplantation of lymphoid-rich multivisceral grafts (2), 
but are most often of donor phenotype in bone marrow recip· 
ients (1, 3, 4). The frequent association of PTLD with the 
Epstein-Barr virus (EBY) (3-7) is similar to that seen with 
Burkitt's lymphoma and with more aggressive B celllympho· 
mas in patients with immune deficiency states (8). 
The EBY+ tumors' unusual susceptibility to immune sur· 
veillance was first demonstrated by involution of the PI'LD 
in organ allograft recipients after reduction (or discontinu-
ance) of immunosuppression (9) with its attendant risk of 
precipitating allograft rejection. The tacit assumption of 
most authors reporting such spontaneous tumor regression 
has been that it is dependent solely on the presence of the 
EBY epitopes. Some authorities have advocated early reo . 
course to irradiation or chemotherapy (10-13). The argu-
ment has been that the benefit of affecting tumor regression 
is too unpredictable to justify risking allograft. rejection by 
prolonged attenuation or discontinuance of immune suppres· 
sion. Efforts to engineer host tumor surveillance by means 
other than lightening immunosuppression have met with 
limited success (14). 
In contrast, restoration of EBY+ tumor surveillance has 
been accomplished under the reverse circumstances, which 
occur in cytoablated EBY+ bone marrow recipients: domi-
nant donor immune system, donor origin of tumors, and 
therapeutic risk of graft· versus-host disease. In these pa· 
tients, PTLD regression has followed the infusion of unmod· 
ified peripheral blood mononuclear cells or EBY·specific cy-
totoxic T cells obtained from the original donor (4,15,16) The 
unavailability of pretransplant recipient leukocytes has pre· 
cluded direct application of this technology to the PTLDs 
developing after organ transplantation. However, we report 
here a strategy in which the recipients' peripheral leukocytes 
were "rearmed" in an interleukin (lL) 2-enriched culture. The 
resulting lymphokine-activated killer (LAK) cell infusate, 
which contained isologous cells with cytotoxic T lymphocyte 
* Abbreviations: EBER. Epstein-Barr virus early RNA; EBV, Ep-
stein-Barr virus; CTL. cytotoxic T lymphocyte; IL, interleukin; LAK. 
lymphokine·activated killer; LMP. latent membrane protein; MHC. 
major histocompatibility complex; NK, natural killer; PBMC. periph· 
eral blood mononuclear cells; PTLD. posttransplant lymphoprolifera-
tive disorder. 
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(CTLl phenotype as well as an augmented natural killer (NK) 
cell portion, was given as a single dose without systemic IL-2 
to four organ recipients with PTLD who were EBV positive 
and to three who were EBV negative. 
MATERlM,S AND METHODS 
Patient and Case Material 
The four male and three female patients were 41-64 years old and 
had received thoracic organ (n=3), liver (n=2), or renal allografts 
(n=2) from 2 months to 12 years earlier. LAK cell therapy was 
considered if there was an incomplete or no response of PTLD to 
reduction or discontinuance of immunosuppression plus antiviral 
therapy (acyclovir or ganciclovir) within a 3·week period. Other 
clinical and pathologic features of the seven cases are summarized in 
Table 1. The diagnosis of PTLD was made with established criteria 
(17, 18). Immunoglobulin gene rearrangement studies (19) demon-
strated monoclonal cell populations in the three PTLD specimens in 
which they were performed (patients 2, 3, and 7, Table 1), and in a 
fourth patient. flow cytometry proved B cell monoclonality (patient 6, 
Table 1). Small specimen sizes or sampling problems precluded 
clonality determination in the other three cases. 
In four patients (patients 1-4), evidence of intra tumoral EBV was 
detected by immunoperoxidase staining for viral latent membrane 
protein (LMP)-1 and by in situ hybridization for EBV early RNA 
(EBERl (20). Both of these assays were negative in tumor samples 
from patients 5, 6, and 7. In addition, Southern blot analysis of 
tumoral DNA from patient 7 also was obtained and failed to demon-
strate EBV sequences. 
LAK Cell Preparation 
Compassionate approval was obtained from the institutional re-
view board for each patient in whom LAK cell therapy was consid· 
ered. The infusates were prepared in the Cellular Adoptive Immu-
notherapy Laboratory at the University of Pittsburgh Cancer 
Institute (21) in accordance with the U.S. Food and Drug Adminis· 
trations Guidelines for Good Laboratory Practice. Peripheral blood 
was collected by leukapheresis on a cell separator (Fenwal 3000; 
Fenwal). Peripheral blood mononuclear cells (PBMC) were isolated 
by centrifugation on Ficoll·Hypaque gradients. treated with phenyl· 
alanine methyl ester to remove cells of the monocyte·macrophage 
lineage, resuspended at a concentration of 2x 106 /ml in AIM·V me-
dium <Gibco. Long Island. NY) supplemented with 6000 IV ofrecom-
binant human IL-2 (Chiron, Emeryville. CAl. and cultured in an 
atmosphere of 50/c CO2 in air at 37°C for 10 to 11 days. On the day of 
LAK cell infusion. the cultures were centrifuged in sterile bottles. 
The cells were resuspended and washed in cold RPMI medium, 
centrifuged again. and pooled into a sterile 50-ml conical tube. The 
cells were then suspended in 5'7c solution of human albumin in 0.9%-
saline and counted. After aliquots for phenotypic and cytotoxicity 
assays were taken, the endotoxin· free cell suspension was injected 
into a transfer pack and given by intravenous infusion over 1 hr. The 
patients were not treated with IL-2. 
Evaluation of LAK Cells 
Phenotype. After 10 to 11 days of culture, the fresh PBMC and the 
LAK cells were studied with two-color flow cytometry. using fluores-
cein or phycoerythrin-labeled monoclonal antibodies purchased from 
Becton Dickinson (Mountain View, CAl. The monoclonal antibody 
specificities were HLA·DR and anti-CD3, -4, -8, ·16, ·19. -25, ·45RA, 
·45RO, and -56. Mouse IgGl and IgG2a isotypes were used as con· 
trois in all assays. 
Cytotoxicity. Acti-.;ty of fresh PBMC and LAK cells at the end of 
their culture was measured in 4-hr StCr release assays (21). Assays 
were performed in triplicate at four different effector-to-target ratios. 
One lytic unit was defined as the number of effector cells required for 
20% lysis of 5 x 103 target cells. The number of lytic units present in 
107 effector cells was calculated with a computer program, as de-
scribed previousiy (22). 
To assess major histocompatibility complex (MHC)-restricted ver-
sus nonrestricted anti-EBV cytotoxicity, quantitative assay of cyto-
toxicity against autologous or third-party EBV-infected B Iympho-
blastoid cell targets, respectively, was done. Calculation of lytic units 
could not be performed because of insufficient numbers of target cells 
for the computer program. 
RESULTS 
LAX Cell Characteristics 
Cell quantity and composition. The number of infused 
LAK cells ranged from 0.52X 1010 to 5.6x 10 lD (Table 1). 
Their phenotype during the 10-11 days of culture shifted 
toward CD56+ cells in all cases compared with the naive 
PBMC (Table 2): a threefold increase in mean number of 
CD3-CD56+ (NK cells) and a sevenfold increase in 
CD3+CD56+ (T cells with NK-like activity) was se'en (Table 
2). 
Cytolytic function. Marked increases in cytotoxic activity 
against Daudi and K562 targets occurred during the culture 
period (Table 2). Cytotoxicity of aliquots of LAK cells against 
autologous (three of three cases) and third-party (HLA-unre-
lated; two of two cases) EBV-infected lymphoblastoid cells 
also was demonstrated in all cases in which the tests were 
done (Table 3). 
Clinical Outcome 
EBV+ patients. The PTLD lesions involuted in all four 
cases, coincident with allograft rejection 3 days and 3 weeks 
after LAK cell infusion in patients 1 and 2, respectively. The 
rejection episodes were easily controlled with prednisone 
therapy. The antitumor effect was particularly obvious in 
patient 2, whose lower-extremity immunoblastic lymphoma 
nodules, which had developed 6 years after cardiac trans-
plantation, could be seen to shrink almost overnight. 
At 12 years after cadaveric renal transplantation, patient 
3 presented with renal failure (15 mVmin creatinine clear-
ance) due to chronic rejection. The diagnosis of PTLD was 
made by CT scan and shown by needle biopsy to be a B cell 
lymphoma with Hodgkin features. Five months later, when 
allograft nephrectomy was performed, tumor was demon-
strated in biopsies of the iliac lymph nodes. LAK cell treat-
ment was given a few days after nephrectomy. Nine months 
after this, all imaging studies were normal. No residual neo-
plasm was present at the time of successful renal retrans-
plantation a few days later. The patient remains tumor-free 
5 months after the retransplantation. 
Patients 1, 2, and 3 are well with no evidence of residual 
tumor 13-16 months after LAK cell treatment (it has been 5 
months since patient 3's renal retransplantation). Neither 
chemotherapy nor radiotherapy has been utilized in any of 
these patients. Patient 4, a double-lung recipient whose poly-
morphic PTLD of undetermined clonality originated in the 
allograft, died of Pseudomonas pneumonia 41 days after in-
fusion. No tumor was found at the autopsy, which was lim-
ited to the thorax. 
EBV- patients. Examination of several specimens each 
from patients 5, 6, and 7 failed to disclose evidence ofEBV. In 
patient 5, LMP-I stains on tissue from the retroperitoneal 
tumor (day 678), chest wall nodule (day 708), and pleural 
fluid (consistent with PTLD, day 910) were all negative. The 
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TABLE 1. Patient population and outcomea 
Tumor Histology of LAK No.ofLAK Patient Allograft Age diagnosis STLD site(s) Monoclonal infusion Outcome 
(poD) PTLD (POD) cells 
EBV+ 
1 Heartllungs, 51 62 Allograft lung Polymorphic ND 105 5.2XI09 Resolved; NED 16 mo PI 
BM PTLD 
2 Heart 64 2138 Legs IBL + 2184 1.5x 1010 Resolved; NED 14 mo PI 
3 Kidney 57 4276 Retroperi toneal IBUHD + 4475 5.6x lOla Resolved; NED 11 mo PI 
nodes 
4 Double lung 41 353 Allograft lung Polymorphic ND 373 6.4x 109 NED at autopsy 41 days PI; 
PTLD pneumonia 
EBV-
5 Liver 63 656 Pelvis, thorax, LCNC NO 727 1.1XlOIO Chemoherapy started 4 days PI; 
extremities patient died 188 days PI 
6 Kidney + BM 52 1098 Abdomen, LCNC + 1133 3.Sx 1010 Radiotherapy (50 Gy) started 14 
cervical days PI, chemotherapystarted 
nodes 60 days PI; patient alive with 
tumor 9 mo PI 
7 Liver 59 1591 Paraspinal LCNC + IS19 1.5x 1010 Chemotherapy started 14 days 
mass, PI; patient died 16 days PI 
intestines, 
liver 
a Abbreviations used in table: BM, bone marrow; HD, Hodgkin's disease-like; IBL, immunoblastic lymphoma; LCNC, largecell noncleaved 
lymphoma; NO, not determined; NED, no evidence of disease; PI, post-infusion; POD, postoperative day. 
TABLE 2. Phenotypic and functional studies of leukapheresed pe-
ripheral blood cells both before and after ex vivo culture in the 
presence of recombinant human IL-2 (mean:': SEM) (n=7f 
Pre-cul ture Post-culture P 
Cell phenotype (%) 
CD3+ 56- 7S=4.5 50=5.6 0.002b 
CD56+ 
CD3+ 2.6=0.6 18=6.0 <O.OOle 
CD3- S.9=27 29.3=5.8 O.OOSb 
DR+ 4.4:': 1.2 34.4:':5.4 <O.OOle 
Cytotoxicity (LV201107 cells) 
Daudi 43=40 2614:,:954 0.002" 
K562 25:':10 5388:': 1596 0.001" 
a Data are expressed mean:': SEM. LV, lytic units. 
b By t test. 
e By Mann·Whitney rank· sum test. 
TABLE 3. Cytotoxicity of LAK cell preparations against autologus 
and third-party EBV' Iymphoblastoid targetsa 
Patient 
Autologous Third·party EBV LCL E:T EBV'LCL 
(% specific kilhngl (% specific killing) 
40:1 21 19 
20:1 25 16 
2 SO:1 25 NO 
40:1 23 NO 
20:1 19 
3 80:1 41 5 
40:1 10 7 
II Abbreviations used in table: E:T, effector-to-target ratio; EBV+ 
LCL, Epstein-Barr virus-transformed, lymphoblastoid cell line; NO, 
not done. 
latter two samples were also negative for EBER by in situ 
hybridization. In patient 6, in situ hybridization for EBER on 
a biopsy of retroperitoneal tumor On day 1099 was negative, 
and LMP-1 stain on a neck mass biopsy performed On day 
1193 was also negative. Both LMP-1 and EBER studies were 
negative on paraspinal mass biopsies from patient 7, per-
formed on days 1591 and 1600. Southern blot analysis for 
EBV was performed on the latter biopsy, and this was neg-
ative for EBV sequences. 
All three recipients (two liver recipients and one kidney 
recipient) had large-cell noncleaved lymphomas. LAK cell 
infusion did not precipitate rejection in any of the patients, 
but it had no effect on the tumors that were subsequently 
treated (also unsuccessfully) with chemotherapy (n=3) or 
irradiation (n=l). One patient is alive with tumor 9 months 
after infusion, and the other two patients died after 16 and 
188 days (Table 1). 
The circumstances of LAK cell treatment in these three 
patients precluded evaluation of efficacy. Dramatic regres-
sion of a large multifocal lymphoma had occurred in patient 
5 after discontinuance of immunosuppression, 2 years after 
liver transplantation. The decision to give LAK cell therapy 
was prompted by a small, residual skin lesion on the thorax. 
When the skin tumor did not disappear by the fourth day 
after LAK cell infusion, multiagent chemotherapy was be-
gun, and repeated in 21- to 28-day cycles until the patient's 
death 6 months later (Fig. 1). Although conventional immu-
nosuppression was never restarted, the patient remained 
rejection-free throughout this period. 
In the other EBV- liver recipient (patient 7), massive 
tumor regrowth following regression was associated with 
resumption of immunosuppression in response to transami-
nase elevations, which were ascribed to a rejection. The pa-
tient, who was moribund by the time LAK cells were given, 
died 16 days later, 2 days after chemotherapy was started. 
The 3-year posttransplant recipient of a cadaver kidney 
and adjunct bone marrow (patient 6) presented with epigas-
tric pain and a large left retroperitoneal mass which had 
shrunk to half of its original volume during 6 weeks off all 
immunosuppression, preceding LAK cell infusion. Fourteen 
days after the infusion, radiotherapy was started because of 
t 
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FIGURE 1. Clinical course of EBV- PTLD in patient 5. The main 
tumor maas shrunk coincident with discontinuation of tacrolimus. 
LAK cell therapy was administered, but any potential benefit was 
obscured by the initiation of chemotherapy beginning 4 days there-
after. 
continued pain. This was given to the left flank mass in 17 
fractions over a 22-day period (total 3060 rads) involving a 
target field of 20X22 em that included the TI0-LS vertebral 
bodies, spleen, liver, and entire supra pelvic abdomen. After a 
rest of 13 days, 2000 more rads were delivered over 5 days to 
a separate vertebral field that included T7-TIO. Although 
less extensive than total lymphoid irradiation, the size of the 
field(s) plus scatter implied a significant immunosuppressive 
effect (Dr. John Flickinger, radiotherapist, Unive"rsity of 
Pittsburgh). Sixty days after LAK cell infusion (6 days after 
completion of the second course of irradiation), CHOP che-
motherapy (cyclophosphamide, doxorubicin, vincristine, and 
prednisone) was begun (six cycles). Although conventional 
immunosuppression has never been restarted, the patient 
has good renal function. A CT scan, which followed six cycles 
of CHOP therapy (7 months after LAK cell infusion) showed 
persistence of the malignancy. 
DISCUSSION 
In bone marrow recipients, for whom drug withdrawal 
usually is not an option, tumor surveillance has been re-
stored with regression of EBV+ PTLD of donor phenotype by 
infusing unmodified peripheral blood lymphocytes or CTLs 
obtained from the original donor (4, 15, 16). Analogous cel-
lular immune modulation of the mirror-image PTLDs of host 
phenotype that develop after organ transplantation has not 
been possible because of the unavailability of naive recipient 
leukocytes. This need could be met in three ways: (1) cryo-
preservation of the patient's pretransplant PBMC proposed 
by Todo et al. (23) for high-risk intestinal candidates, (2) the 
use of a surrogate leukocyte donor HLA identical to that of 
the recipient (as reported by Emanuel et al. (24)), or (3) the 
infusion offunctionally resurrected autologous cells. The first 
option is impractical, and the second is inconvenient, even if 
an HLA-identica1 donor can be found, as in Emanuel's case 
(24). Evaluation of the third option was our objective, using 
LAK cells. 
Cellular immune modulation of PTLD in organ transplant 
patients has been based largely on the assumption that effi-
cacy required an EBY+ target (25, 26). Because control of 
EBY replication in vivo is primarily by EBY-specific CTL (B, 
25, 26), and since NK cells have also shown effector activity 
against these cells in vitro (27, 28), the presence of both 
phenotypes in the LAK cell infusate was reassuring. A ther-
apeutic benefit was seen in all four EBY+ cases. Although 
undesirable consequences of cellular immunotherapy (rejec-
tion in our organ recipients and graft-versus-host disease 
after bone marrow transplantation [4]) have been manage-
able, these might be preventable by isolation with limiting 
dilution techniques of epitope-specific CTL, as has already 
been reported in bone marrow recipients at high risk for 
cytomegalovirus infection (29) or for complications of EBY 
(16). However, before this prediction can be made with con-
fidence, more data are needed on the extent of cross-reactions 
between EBY and class I MHC epitopes (30, 31). In the 
present series, a disproportionate number of patients lacked 
evidence of intra tumoral EBY. This is not representative of 
our entire PTLD patient population, in which such lesions 
are exceptional. 
The results in the EBY+ patients fit well within the con-
text of PTLD and its EBY association that has evolved over 
the last 15 years (25, 26). However, acceptance of this ass0-
ciation as an immutable precondition for LAK cell-responsive 
PTLD was an underlying factor in treatment decisions in the 
patients with EBY- tumors. By the time LAK cell therapy 
was started, all three of the EBY- patients had proved their 
ability to restore tumor surveillance with no other manage-
ment change than discontinuance of immunosuppression 
(see Fig. 1). In our opinion, this capability was interdicted by 
premature intervention with high-dose irradiation in one 
case, and with a highly immunosuppressive chemotherapeu-
tic lymphoma protocol in all three. 
Early recourse to chemotherapy has been recommended as 
initial therapy for PTLD (whether EBY positive or negative) 
with increasing frequency during the last dozen years (l0-
13). In contrast, our opinion is that management must begin 
with reduction or discontinuance of immunosuppression (9) 
and that chemotherapy (or multiregional radiotherapy) 
should be the last step, if it is used at all, in the treatment of 
PTLD. Retardation of immunologic recovery by chemother-
apy or high-dose radiotherapy was contraindicated in two, 
and probably all three, of our EBY- patients, just as in those 
who were EBY+. Because this conventional antitumor ther-
apy worked at cross-purposes with the strategy of surveil-
lance restoration, it remains to be determined whether EBV-
tumors can be treated with LAK cells. Furthermore, we em-
phasize that LAK cell therapy is only a bridge to the ultimate 
objective of natural surveillance and that repeat infusions 
can be given. Future studies should seek to evaluate donor or 
recipient origin of the tumors in order to document whether 
MHC restriction is a prerequisite for PTLD remission in the 
setting of LAK cell administration. Finally. in all cases, a 
variable period of reduced immunosuppression preceded 
LAK cell therapy. Failure of the tumors to regress was the 
1204 TRANSPLANTATION Vol. 63, No.9 
impetus for LAK cell administration. We cannot discount a 
contributory effect oflowered or reduced immunosuppression 
on tumor regression, and we do not recommend at this time 
that LAK cell therapy be undertaken in the absence of a trial 
of lowered immunosuppression. 
Pl'LD is estimated to occur in 2-5% of organ allograft 
recipients and in 1% of bone marrow recipients (32, 33). It 
has been viewed as an enigmatic complication of transplan-
tation. However, 3 years before PTLD were first reported in 
humans (34-36), Schwartz, Beldotti, and co-workers (37,38) 
described similar tumors in an F 1 hybrid mouse model in 
which lesions indistinguishable from clinical PTLD regularly 
developed after the induction of low-level asymptomatic do-
nor leukocyte chimerism. Although Schwartz concluded that 
the tumors resulted from a graft-versus-host reaction (38), 
the relevance of these tumors to human PTLD could be 
appreciated after the discovery a quarter century later of 
donor leukocyte microchimerism in organ recipients (39, 40), 
and of a residual host leukocyte population (41, 42) in all 
bone marrow recipients previously thought to have complete 
donor leukocyte chimerism (43). Then, it was evident that all 
organ allografts are potentially "lymphomagenic," particu-
larly when the cofactors of T cell-directed immunosuppres-
sion and viral infection including EBV are added (43). 
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